228760.Kq
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
Business. The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
The company maintains a strong liquidity position, with cash and equivalents amounting to KRW 16,314,618,920 and a current ratio of 17.75, indicating a high ability to meet short-term obligations. The price-to-book ratio of 2.88 suggests that the market values the company at a premium relative to its book value, while the debt-to-equity ratio of 0.02 indicates a low reliance on debt financing.
Profitability metrics reveal a challenging financial position, with a return on equity of -7.81% and a return on assets of -7.44%, both significantly below the industry median for biotechnology firms. The company reported a net loss of KRW 8,985,720,500 and an operating loss of KRW 11,305,781,840, highlighting the need for operational improvements or strategic shifts to restore profitability.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits the ability to offset losses in one area with gains in another.
Looking ahead, the company is expected to maintain a flat revenue trajectory, with no significant growth or decline projected in the current or next fiscal year. The absence of capital expenditure growth and the continued negative operating cash flow suggest that the company is not investing in expansion or innovation at a meaningful level.
The risk assessment indicates a low probability of dilution and no immediate liquidity concerns. However, the company's negative net income and operating cash flow raise questions about long-term sustainability. The absence of dilution flags is a positive sign, but the company may need to consider equity or debt financing to fund future operations or growth initiatives.
Recent filings and transcripts do not indicate any major strategic shifts or significant events that would alter the company's current trajectory. The company remains in a development phase, with a focus on maintaining its existing operations and managing cash flow.
- The company has a strong liquidity position with a high current ratio and significant cash reserves.
- Profitability is negative, with both return on equity and return on assets below zero.
- Revenue is concentrated in a single business segment, increasing exposure to market-specific risks.
- No significant growth or decline in revenue is expected in the near term.
- The company faces low dilution risk but may need to consider financing options to support future operations.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 228760.KQ Market data — financials · 2026-05-26